# Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

> **NCT06954090** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Steno Diabetes Center Copenhagen** · enrollment: 50 (estimated)

## Conditions studied

- Type 2 DM
- Type 2 DM /Diabetic Nephropathy
- Albuminuria

## Interventions

- **DRUG:** Semaglutide, 1.34 mg/mL
- **DRUG:** Finerenone Oral Tablet
- **DRUG:** Dapagliflozin (DAPA)

## Key facts

- **NCT ID:** NCT06954090
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-20
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954090, "Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06954090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*